Avantor Performance Materials Names New CEO
PTSM: Pharmaceutical Technology Sourcing and Management
Avantor Performance Materials appoints Michael Stubblefield as CEO.
Avantor Performance Materials, a manufacturer and supplier of high-performance chemistries, reported the appointment of Michael Stubblefield as CEO. Stubblefield has over 20 years of global chemical industry leadership experience. Most recently, Stubblefield served as a senior expert for the Chemicals Practice of McKinsey & Company.
In his role as CEO, Stubblefield will oversee all aspects of Avantor’s global operations in its four business areas, which include laboratory products, pharmaceuticals, electronic materials, and diagnostics. He will be based at Avantor’s corporate headquarters in Center Valley, PA. Stubblefield holds an MBA from Texas A&M University-Corpus Christi, and a Bachelor of Science degree in chemical engineering from the University of Utah.
Source: Avantor Performance Materials
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
